Evidence map›Paper›PMID 31565223›Full record

ArticleBiomedical reports2019

Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing.

Satoshi Fujii, Takayuki Yoshino, Kentaro Yamazaki, Kei Muro, Kensei Yamaguchi, Tomohiro Nishina, Satoshi Yuki, Eiji Shinozaki, Kohei Shitara, Hideaki Bando and 15 more

Open access · diamondAbstract read
In one paragraph

Article in Biomedical reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Validation of Modaplex POLE mutation assay in endometrial carcinoma.Virchows Archiv : an international journal of pathology · 2023
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 13 institutions in 1 country.

Satoshi FujiiDivision of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba 277-8577, Japan.
Takayuki YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan.
Kentaro YamazakiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi, Shizuoka 411-8777, Japan.
Kei MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi 464-8681, Japan.
Kensei YamaguchiDepartment of Gastrointestinal Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-0063, Japan.
Tomohiro NishinaDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime 791-0280, Japan.
Satoshi YukiDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Hokkaido 060-8648, Japan.
Eiji ShinozakiDepartment of Gastrointestinal Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-0063, Japan.
Kohei ShitaraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan.
Hideaki BandoDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi 464-8681, Japan.
Sachiyo MimakiDivision of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba 277-8577, Japan.
Chikako NakaiG&G Science Co. Ltd., Fukushima 960-1242, Japan.
Koutatsu MatsushimaG&G Science Co. Ltd., Fukushima 960-1242, Japan.
Yutaka SuzukiDepartment of Computational Biology, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba 277-8562, Japan.
Kiwamu AkagiDivision of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama 362-0806, Japan.
Takeharu YamanakaDepartment of Biostatistics, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
Shogo NomuraBiostatistics Division, Center for Research and Administration and Support, National Cancer Center, Kashiwa, Chiba 277-8577, Japan.
Hiroyasu EsumiResearch Institute for Biomedical Sciences, Tokyo University of Science, Noda, Chiba 278-0022, Japan.
Masaya SugiyamaGenome Medical Sciences Project, National Center for Global Health and Medicine, Chiba 277-8516, Japan.
Nao NishidaGenome Medical Sciences Project, National Center for Global Health and Medicine, Chiba 277-8516, Japan.
Masashi MizokamiGenome Medical Sciences Project, National Center for Global Health and Medicine, Chiba 277-8516, Japan.
Yasuhiro KohThird Department of Internal Medicine, Wakayama Medical University, Wakayama 641-8509, Japan.
Yukiko AbeG&G Science Co. Ltd., Fukushima 960-1242, Japan.
Atsushi OhtsuNational Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan.
Katsuya TsuchiharaDivision of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba 277-8577, Japan.
National Cancer Center Hospital East · JPNational Center for Global Health and Medicine · JPAichi Cancer Center · JPChiba Cancer Center · JPJapanese Foundation For Cancer Research · JPHokkaido University Hospital · JPSaitama Cancer Center · JPShikoku Cancer Center · JPShizuoka Cancer Center · JPThe University of Tokyo · JPTokyo University of Science · JPWakayama Medical University · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To enable the widespread application of genomic medicine, the extraction of genomic DNA from thin sections of archived formalin-fixed and paraffin-embedded (FFPE) tissue blocks for next-generation sequencing (NGS) is often necessary. However, there are currently no guidelines available on which specific regions of the microtome sections to use for macrodissection with respect to the histopathological factors observed under microscopic examination. The aim of this study was to clarify the relationship between histopathological factors and DNA quality, and to standardize the macrodissection method for more efficient implementation of NGS. FFPE tissue specimens of 218 patients from the Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics study were used to investigate the relationship between 15 histopathological factors and the quantitative ratio of double-stranded DNA (dsDNA) to total nucleic acids, as well as the ∆ crossing point value of each tissue specimen. Multivariate logistic regression analysis revealed that specimen storage of ≥3 years was negatively associated with dsDNA quality (P=0.0007, OR: 4.30, 95% CI: 1.85-10.04). In contrast, the presence of a mucus pool was positively associated with dsDNA quality (P=0.0308, OR: 0.23, 95% CI: 0.06-0.87). Metastatic tumors and longer specimen storage periods were significantly associated with lower ∆Cp values (P=0.0007, OR: 4.43, 95% CI: 1.87-10.49; and P=0.0003, OR: 5.51, 95% CI: 2.18-13.95, respectively). Therefore, macrodissection should not be performed on specimens exhibiting histopathological factors associated with poor DNA quality. In particular, the use of tissue blocks with a storage period of <3 years allows the extraction of genomic DNA suitable for NGS.

Indexed as

∆CpdsDNAformalin-fixed and paraffin-embedded tissue specimenhistopathological factorsnext-generation sequencing

Identifiers

PMID31565223
PMCPMC6759515
OpenAlexW2969973799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.